自体造血干细胞移植在多发性骨髓瘤治疗中的优化和生存趋势

李娟; 刘俊茹

doi:10.13201/j.issn.1004-2806.2021.07.001

自体造血干细胞移植在多发性骨髓瘤治疗中的优化和生存趋势

李娟^,,
刘俊茹

- 中山大学附属第一医院(广州, 510080)
基金项目:
中山大学临床医学研究5010计划项目(No:2017005)

详细信息

通讯作者: 李娟,E-mail:ljuan@mail.sysu.edu.cn,二级教授,一级主任医师,博士生导师,中山大学名医,中山大学血液病研究所所长,中山大学附属第一医院内科主任、血液内科主任。现任广东省医师协会血液科医师分会主任委员、广东省医学会血液病学分会前任主任委员、中华医学会血液学分会常委和浆细胞疾病学组组长、中国医师协会血液科医师分会常委和多发性骨髓瘤专委会副主委、国际骨髓瘤协会成员、亚洲骨髓瘤网成员等职务。主持过或正主持的基金包括国家自然科学基金等20多项,以第一作者或通讯作者发表论文200余篇,SCI收录70余篇,主编专著6部,作为主要执笔人参与编写中国骨髓瘤诊治指南(连续六版)。以第一完成人主持的骨髓瘤相关成果分别获广东省科技进步一等奖和三等奖、华夏医学科技奖二等奖、第六届中国女医师协会五洲女子科技奖(临床医学科研创新奖)。

中图分类号: R733.3

收稿日期: 2021-04-02

Optimization and survival trends of autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma

LI Juan^,,
LIU Junru

More Information

Corresponding author: LI Juan, E-mail: ljuan@mail.sysu.edu.cn

Received Date: 02 April 2021

摘要

- 多发性骨髓瘤 /
- 自体造血干细胞移植 /
- 生存趋势
- multiple myeloma /
- autologous stem cell transplantation /
- survival trends

HTML全文

参考文献(30)

[1]	Srour SA,Bashir Q,Milton DR,et al.Survival trends in multiple myeloma after autologous hematopoietic stem cell transplantation[J].Blood,2020,136(Supplement 1):24-25.
[2]	Attal M,Harousseau JL,Stoppa AM,et al.A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.Intergroupe Français du Myélome[J].N Engl J Med,1996,335(2):91-97.
[3]	Gay F,Oliva S,Petrucci MT,et al.Chemotherapy plus lenalidomide versus autologous transplantation,followed by lenalidomide plus prednisone versus lenalidomide maintenance,in patients with multiple myeloma:a randomised,multicentre,phase 3 trial[J].Lancet Oncol,2015,16(16):1617-1629.
[4]	Attal M,Lauwers-Cances V,Hulin C,et al.Lenalidomide,Bortezomib,and dexamethasone with transplantation for myeloma[J].N Engl J Med,2017,376(14):1311-1320.
[5]	Perrot A,Lauwers-Cances V,Cazaubiel T,et al.Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma:long-term follow-up analysis of the IFM 2009 trial[J].Blood,2020,136(Supplement 1):39.
[6]	Cavo M,Gay F,Beksac M,et al.Upfront autologous hematopoietic stem-cell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly diagnosed multiple myeloma:long-term follow-up analysis of the randomized phase 3 EMN02/HO95 study[J].Blood,2020,136(Supplement 1):37-38.
[7]	Gay F,Cerrato C,Scalabrini RD,et al.Carfilzomib lenalidomide dexamethasone(KRd)with or without transplantation in newly diagnosed myeloma(FORTE TRIAL):efficacy according to risk status:S872[J].HemaSphere,2019,3(S1):390-391.
[8]	Gay,F,Musto P,Scalabrini DR,et al.Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized Forte Trial[J].Blood,2020,136(Supplement 1):35-37.
[9]	中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020,59(5):341-346.
[10]	Roussel M,Hebraud B,Hulin C,et al.Twice weekly induction with ixazomib-lenalidomide-dexamethasone(IRd)combination followed by extended IRD consolidation and lenalidomide maintenance in transplant eligible patients with newly diagnosed multiple myeloma(NDMM):A phase 2 atudy from the Intergroupe Francophone Du Myelome(IFM 2014-03)[J].Blood,2019,134(Supplement_1):3159.
[11]	Kumar SK,Jacobus SJ,Cohen AD,et al.Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation(ENDURANCE):a multicentre,open-label,phase 3,randomised,controlled trial[J].Lancet Oncol,2020,21(10):1317-1330.
[12]	Usmani SZ,Ailawadhi S,Sexton R,et al.Primary analysis of the randomized phase II trial of bortezomib,lenalidomide,dexamthasone with/without elotuzumab for newly diagnosed,high-risk multiple myeloma(SWOG-1211)[J].J Clin Oncol,2020,38(suppl;abstr 8507).
[13]	Weisel K,Asemissen AM,Besemer B,et al.Depth of response to isatuximab,carfilzomib,lenalidomide,and dexamethasone(Isa-KRd)in front-line treatment of high-risk multiple myeloma:Interim analysis of the GMMG-CONCEPT trial[J].J Clin Oncol,2020,38(suppl;abstr 8508).
[14]	Rajkumar SV.Multiple myeloma:2020 update on diagnosis,risk-stratification and management[J].Am J Hematol,2020,95(5):548-567.
[15]	Munshi NC,Avet-Loiseau H,Rawstron AC,et al.Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma:A Meta-analysis[J].JAMA Oncol,2017,3(1):28-35.
[16]	Kaufman JL,Laubach JP,Sborov D,et al.Daratumumab(DARA)plus lenalidomide,bortezomib,and dexamethasone(RVd)in patients with transplant-eligible newly diagnosed multiple myeloma(NDMM):updated analysis of Griffin after 12 months of maintenance therapy[J].Blood,2020,136(Supplement 1):45-46.
[17]	Moreau P,Attal M,Hulin C,et al.Bortezomib,thalidomide,and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma(CASSIOPEIA):a randomised,open-label,phase 3 study[J].Lancet(London,England),2019,394(10192):29-38.
[18]	Xu L,Liu J,Huang B,et al.Comparison of efficacy,safety,patients' quality of life,and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma[J].Cancer Med,2021,10(5):1656-1667.
[19]	Giralt S,Costa L,Schriber J,et al.Optimizing autologous stem cell mobilization strategies to improve patient outcomes:consensus guidelines and recommendations[J].Biol Blood Marrow Transplant,2014,20(3):295-308.
[20]	Mina R,Bonello F,Milone G,et al.On-demand plerixafor with cyclophosphamide and G-CSF for hematopoietic stem-cell mobilization in multiple myeloma patients:preliminary results of a prospective observational study(MOZOBL06877)[J].Blood,2020,136(Supplement 1):13-14.
[21]	Moreau P,Facon T,Attal M,et al.Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial[J].Blood,2002,99(3):731-735.
[22]	谷景立,李娟,刘俊茹,等.大剂量美法仑与环磷酰胺、依托泊苷联合白消安预处理方案在多发性骨髓瘤自体造血干细胞移植中的比较[J].中华血液学杂志,2019,40(9):732-737.
[23]	Farag S,Bacher U,Legros M,et al.High-dose chemotherapy with bendamustin and melphalan improves the rate of complete remission in myeloma patients in first remission compared to standard melphalan alone[J].Blood,2020,136(Supplement 1):39-40.
[24]	Li AY,Atenafu EG,Bernard RS,et al.Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency:an institutional comparison between two eras[J].Bone Marrow Transplant,2020,55(3):578-585.
[25]	Garderet L,Ouldjeriouat H,Bekadja MA,et al.Acceptable toxicity and good hematological and renal responses after autologous hematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant:A prospective SFGM-TC observational study[J].Blood,2020,136(Supplement 1):38-39.
[26]	Vaxman I,Visram A,Kumar SK,et al.Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents[J].Blood,2020,136(Supplement 1):12-13.
[27]	Stadtmauer EA,Pasquini MC,Blackwell B,et al.Autologous transplantation,consolidation,and maintenance therapy in multiple myeloma:results of the BMT CTN 0702 trial[J].J Clin Oncol,2019,37(7):589.
[28]	Gay F,Jackson G,Rosiňol L,et al.Maintenance treatment and survival in patients with myeloma:A systematic review and network meta-analysis[J].JAMA Oncol,2018,4(10):1389-1397.
[29]	Dimopoulos MA,Gay F,Schjesvold F,et al.Oral ixazomib maintenance following autologous stem cell transplantation(TOURMALINE-MM3):a double-blind,randomised,placebo-controlled phase 3 trial[J].Lancet,2019,393(10168):253-264.
[30]	Nandakumar B,Kapoor P,Binder M,et al.Continued improvement in survival of patients with newly diagnosed multiple myeloma(MM)[J].Blood,2020,136(Supplement 1):30-31.